The only UK certified centre right now

In the UK, ChondroFiller injection is currently available at one certified centre: the London Cartilage Clinic at 66 Harley Street, London. Professor Paul Y.F. Lee, who introduced the technique to the UK as an outpatient ultrasound-guided injection, leads its delivery there. That single-centre picture is not a gap in the data — it reflects what the treatment genuinely requires to be done safely and correctly.

ChondroFiller is a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany and imported under a separate individual prescription for each patient. Delivering it accurately demands real-time ultrasound guidance infrastructure, MRI-based defect-mapping expertise, and the clinical logistics to manage per-patient prescription import — capabilities that sit outside the routine setup of most general GP or sports-medicine injection clinics. Where those conditions are met, the treatment can be offered; where they are not, it should not be.

There is currently no NHS pathway and no active public-funding pilot for ChondroFiller injection in the UK, so access is entirely on a self-funded private basis.

For patients based in Scotland, Wales, Northern Ireland, or the English regions, travelling to London is the practical route. A remote clinical assessment is available as a starting point, allowing a clinician to review existing imaging and medical history before any travel is committed to. International patients can also arrange for consultation, imaging review, and treatment to be co-ordinated into a single visit.

Whether your joint damage is suitable

Not every joint problem is a candidate for ChondroFiller injection, and the key distinction is not age or how worn the joint looks on an X-ray — it is the pattern of damage.

The treatment is designed for focal cartilage lesions graded ICRS III or IV: damage that has gone through most or all of the cartilage layer, reaching deep fissuring or exposed bone, but contained within a defined patch rather than spread across the joint surface. A defect of up to approximately 3 cm² is covered by a single implant box, and the protocol can be extended for larger areas where needed. What falls outside scope is diffuse or generalised loss — where the cartilage surface is broadly degraded across multiple areas of the joint. For that pattern, the scaffold has no contained boundary to gel into and stabilise.

A widely held misconception is that a 'bone on bone' finding on X-ray, or being over a certain age, rules treatment out. It does not. There is no upper age limit on the injection pathway, and joint mechanics and defect containment matter considerably more than an X-ray grade alone. Whether the joint is well-aligned, whether the surrounding cartilage provides a stable margin, and whether load distribution is appropriate are the clinically meaningful questions at assessment.

Two contraindications do apply: a known allergy to collagen, and active infection within the joint. Either would preclude treatment until resolved. All of this is confirmed at the first clinical appointment through imaging review, physical examination, and a structured suitability check.

How to start: no GP referral required

No referral from a GP or specialist is needed to begin. The pathway is entirely private and self-funded, so the starting point is a direct patient enquiry rather than a waiting list or gatekeeping step.

Two routes into assessment are available. The first is a free discovery call — a short conversation to understand joint history and what the treatment might offer. The second is an 8-question online suitability assessment that takes approximately two minutes to complete. Either approach helps establish which of three pathways is likely to suit before a formal consultation is booked: a standalone ChondroFiller injection, the Liquid Cartilage keyhole procedure, or a combination of the two.

Patients travelling from outside London can begin remotely. Existing imaging and clinical history can be reviewed before any commitment to travel is made, allowing the first clinic visit to be purposeful rather than exploratory.

The one-hour formal consultation that follows either starting point is where imaging is reviewed in detail, the cartilage defect is mapped, and a written treatment plan is agreed with the clinical team at the London Cartilage Clinic on Harley Street.

What happens at your first consultation

Arriving knowing what to expect makes the appointment more productive. The session runs for approximately one hour and follows a clear three-part structure: a clinical history review, a physical examination of the joint, and an analysis of your imaging.

The history discussion covers pain patterns, how long symptoms have been present, previous treatments tried, and any relevant medical background. The physical examination that follows assesses range of movement, joint stability, and whether there is swelling — all of which inform how the joint is functioning, not just what the scans show.

The imaging review is where defect size and depth are mapped precisely. For this to happen at the appointment itself rather than at a follow-up, patients should arrive with recent weight-bearing X-rays and an MRI of the affected joint. Without both, the clinical picture is incomplete and a decision on the correct pathway cannot be made on the day.

By the end of the hour, the clinician will have confirmed whether ChondroFiller injection is appropriate, identified the defect location and volume, and outlined which treatment plan fits the clinical picture. Attending the consultation does not commit a patient to proceeding — it is a decision-making appointment, and patients leave with a written treatment plan rather than a booking for treatment.

What happens on injection day

Unlike surgical cartilage procedures, the ChondroFiller injection takes place entirely in an outpatient clinic setting — no theatre booking, no general anaesthetic, and no incision of any kind. The appointment runs for approximately 30 to 45 minutes.

Placement is carried out under real-time ultrasound guidance, which allows the clinician to direct the needle with precision into the cartilage defect and confirm positioning throughout. IV antibiotic cover is given on the day as standard.

Once delivered into the defect, the injectable collagen scaffold self-gels within minutes, forming a stable, bioresorbable matrix that fills the damaged area and holds its position. Over the weeks and months that follow, progenitor cells from the surrounding tissue migrate into this scaffold and, through a process called matrix-induced chondrogenesis, begin to differentiate into chondrocytes — the cells responsible for cartilage. The scaffold supports that biological process rather than substituting for it; the repair is driven by the body's own tissue response.

Early recovery centres on one practical adjustment: limiting heavy joint loading for approximately six weeks while the matrix stabilises and the repair process establishes itself. Most patients can manage day-to-day activities during this period; the restriction targets impact loading and sustained weight-bearing rather than all movement. Recovery is generally less complex than the rehabilitation required after multi-stage cartilage surgery, though the right timeline for each patient is confirmed at the follow-up appointment six weeks after the injection.

Cost and insurance pre-authorisation

Pricing at the London Cartilage Clinic is structured by volume and quoted all-inclusive — no separate facility fees, imaging surcharges, or follow-up charges are added. One box costs £3,000; two boxes, £5,500; three boxes, £8,000. Each tier covers the consultation, MRI review, ultrasound guidance, the product itself, IV antibiotic cover on the day, and the six-week follow-up appointment.

For patients who require advanced combination approaches — such as a dual injection pairing ChondroFiller with Arthrosamid for more complex osteoarthritic presentations, or the Tri-Active Therapy incorporating autologous mesenchymal stem cells — pricing ranges from £6,000 to £11,000 depending on the protocol.

On insurance: pre-authorisation is occasionally granted on a case-by-case basis. The procedures are billed under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500; approvals have been reported most often through Bupa, Aviva, and WPA. Individual policy terms differ, however, and approval is not guaranteed. Critically, written pre-authorisation must be in place before treatment takes place — retrospective claims are not accepted.

In practice, most patients plan for ChondroFiller injection as a self-funded procedure from the outset, and budgeting on that basis avoids delays if an insurer declines.